# BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.**

=> d ibib abs hitstr l8 1-2

L8 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:763323 HCAPLUS
DOCUMENT NUMBER: 135:315598
TITLE: Methods for proteomic analysis using activity based probes for target proteins
INVENTOR(S): **Cravatt, Benjamin F.; Sorensen, Erik ; Patricelli, Matthew; Lovato, Martha; Adam, Gregory**
PATENT ASSIGNEE(S): Scripps Research Institute, USA
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001077684 | A2 | 20011018 | WO 2000-US34187 | 20001215 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2002045194 | A1 | 20020418 | US 2000-738954 | 20001215 |
| EP 1275006 | A2 | 20030115 | EP 2000-990226 | 20001215 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| US 2002040275 | A1 | 20020404 | US 2001-836148 | 20010416 |
| US 2002064799 | A1 | 20020530 | US 2001-836145 | 20010416 |
| US 2002182652 | A1 | 20021205 | US 2002-158498 | 20020529 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 2000-195954P | P | 20000410 |
| US 2000-212891P | P | 20000620 |
| US 2000-222532P | P | 20000802 |
| US 2000-738271 | A1 | 20001215 |
| US 2000-738954 | A1 | 20001215 |
| WO 2000-US34187 | W | 20001215 |

OTHER SOURCE(S): MARPAT 135:315598

AB The present invention provides methods for analyzing proteomes, as cells or lysates. The anal. is based on the use of probes that have specificity to the active form of proteins, particularly enzymes and receptors. The probes can be identified in different ways. In accordance with the present invention, a method is provided for generating and screening compd. libraries that are used for the identification of lead mols., and for the parallel identification of their biol. targets. By appending specific functionalities and/or groups to one or more binding moieties, the reactive functionalities gain binding affinity and specificity for particular proteins and classes of proteins. Such libraries of candidate compds., referred to herein as activity-based probes, or ABPs, are used to screen for one or more desired biol. activities or target proteins.

IT **38078-09-0**, (Diethylamino)sulfur trifluoride
RL: RCT (Reactant); RACT (Reactant or reagent)
(DAST; methods for proteomic anal. using activity based probes for target proteins)

RN 38078-09-0 HCAPLUS
CN Sulfur, (N-ethylethanaminato)trifluoro-, (T-4)- (9CI) (CA INDEX NAME)



IT **259270-28-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(FP-biotin; methods for proteomic anal. using activity based probes for target proteins)
RN 259270-28-5 HCAPLUS
CN Phosphonofluoridic acid, [10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **259270-29-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(FP-fluorescein; methods for proteomic anal. using activity based probes for target proteins)
RN 259270-29-6 HCAPLUS
CN Phosphonofluoridic acid, [10-[[5-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]pentyl]amino]-10-oxodecyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT **9028-86-8**, Aldehyde dehydrogenase
RL: ANT (Analyte); PRP (Properties); ANST (Analytical study)
(cytosolic class I; methods for proteomic anal. using activity based

probes for target proteins)
RN 9028-86-8 HCAPLUS
CN Dehydrogenase, aldehyde (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **9027-41-2**, Hydrolase
RL: ANT (Analyte); CAT (Catalyst use); PRP (Properties); ANST (Analytical study); USES (Uses)
(methods for proteomic anal. using activity based probes for target proteins)
RN 9027-41-2 HCAPLUS
CN Hydrolase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **342792-17-0P 342792-18-1P 342792-19-2P**
**342792-20-5P 342792-21-6P 342792-22-7P**
**342792-23-8P 342792-24-9P 342792-25-0P**
**342792-26-1P 342792-27-2P 367480-61-3P**
RL: ARG (Analytical reagent use); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)
(methods for proteomic anal. using activity based probes for target proteins)
RN 342792-17-0 HCAPLUS
CN 2-Pyridinesulfonic acid, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342792-18-1 HCAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-2-oxo-N-[5-[[1-oxo-10-[(phenylsulfonyl)oxy]decyl]amino]pentyl]-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342792-19-2 HCAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-N-[5-[[10-[[(4-methylphenyl)sulfonyl]oxy]-1-oxodecyl]amino]pentyl]-2-oxo-, (3aS,4S,6aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342792-20-5 HCAPLUS
CN Benzenesulfonic acid, 4-methoxy-, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 342792-21-6 HCAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-N-[5-[[10-[(methylsulfonyl)oxy]-1-oxodecyl]amino]pentyl]-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 342792-22-7 HCAPLUS
CN 1-Butanesulfonic acid, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 342792-23-8 HCAPLUS
CN 1-Octanesulfonic acid, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342792-24-9 HCAPLUS
CN Benzenesulfonic acid, 4-nitro-, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342792-25-0 HCAPLUS
CN 8-Quinolinesulfonic acid, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342792-26-1 HCAPLUS
CN 2-Naphthalenesulfonic acid, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342792-27-2 HCAPLUS
CN 2-Thiophenesulfonic acid, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 367480-61-3 HCAPLUS
CN Phosphonofluoridic acid, [25-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-13,21-dioxo-3,6,9,12-tetraoxa-14,20-diazapentacos-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **16156-52-8P 117800-97-2P 126092-21-5P**
RL: ARU (Analytical role, unclassified); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation)
(methods for proteomic anal. using activity based probes for target proteins)
RN 16156-52-8 HCAPLUS
CN Methanesulfonic acid, octyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 117800-97-2 HCAPLUS
CN 2-Pyridinesulfonic acid, octyl ester (9CI) (CA INDEX NAME)



RN 126092-21-5 HCAPLUS
CN 2-Pyridinesulfonic acid, ethyl ester (9CI) (CA INDEX NAME)



IT **52-90-4**, Cysteine, properties **56-84-8**, L-Aspartic acid, properties **56-86-0**, L-Glutamic acid, properties **58-85-5**, Biotin **71-00-1**, Histidine, properties **107-29-9D**, .alpha.-halo derivs. **13537-32-1D**, Fluorophosphoric acid, derivs.
RL: PRP (Properties)
(methods for proteomic anal. using activity based probes for target proteins)
RN 52-90-4 HCAPLUS
CN L-Cysteine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 56-84-8 HCAPLUS
CN L-Aspartic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 56-86-0 HCAPLUS
CN L-Glutamic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 58-85-5 HCAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 71-00-1 HCAPLUS
CN L-Histidine (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 107-29-9 HCAPLUS
CN Acetaldehyde, oxime (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 13537-32-1 HCAPLUS
CN Phosphorofluoridic acid (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



IT **93-11-8**, 2-Naphthalenesulfonyl chloride **98-09-9**, Benzenesulfonyl chloride **98-59-9 98-68-0** **98-74-8 111-87-5**, 1-Octanol, reactions **112-43-6**, 10-Undecen-1-ol **112-60-7 121-44-8**, Triethylamine, reactions **122-52-1**, Triethylphosphite **124-63-0**, Methanesulfonyl chloride **2386-60-9**, 1-Butanesulfonyl chloride **2857-97-8**, Trimethylsilyl bromide **6066-82-6**, N-Hydroxysuccinimide **7790-28-5 7795-95-1**, 1-Octanesulfonyl chloride **10049-08-8**, Ruthenium chloride (RuCl3) **16629-19-9**, 2-Thiophenesulfonyl chloride **18704-37-5**, 8-Quinolinesulfonyl chloride **66715-65-9**, 2-Pyridylsulfonyl chloride **115416-38-1**, 5-(Biotinamido)pentylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(methods for proteomic anal. using activity based probes for target

proteins)
RN 93-11-8 HCAPLUS
CN 2-Naphthalenesulfonyl chloride (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 98-09-9 HCAPLUS
CN Benzenesulfonyl chloride (8CI, 9CI) (CA INDEX NAME)



RN 98-59-9 HCAPLUS
CN Benzenesulfonyl chloride, 4-methyl- (9CI) (CA INDEX NAME)



RN 98-68-0 HCAPLUS
CN Benzenesulfonyl chloride, 4-methoxy- (9CI) (CA INDEX NAME)



RN 98-74-8 HCAPLUS
CN Benzenesulfonyl chloride, 4-nitro- (9CI) (CA INDEX NAME)



RN 111-87-5 HCAPLUS
CN 1-Octanol (9CI) (CA INDEX NAME)



RN 112-43-6 HCAPLUS
CN 10-Undecen-1-ol (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 112-60-7 HCAPLUS
CN Ethanol, 2,2'-[oxybis(2,1-ethanediyloxy)]bis- (9CI) (CA INDEX NAME)



RN 121-44-8 HCAPLUS
CN Ethanamine, N,N-diethyl- (9CI) (CA INDEX NAME)



RN 122-52-1 HCAPLUS
CN Phosphorous acid, triethyl ester (8CI, 9CI) (CA INDEX NAME)



RN 124-63-0 HCAPLUS
CN Methanesulfonyl chloride (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 2386-60-9 HCAPLUS
CN 1-Butanesulfonyl chloride (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 2857-97-8 HCAPLUS
CN Silane, bromotrimethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 6066-82-6 HCAPLUS
CN 2,5-Pyrrolidinedione, 1-hydroxy- (9CI) (CA INDEX NAME)



RN 7790-28-5 HCAPLUS
CN Periodic acid (HIO4), sodium salt (8CI, 9CI) (CA INDEX NAME)



RN 7795-95-1 HCAPLUS
CN 1-Octanesulfonyl chloride (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 10049-08-8 HCAPLUS

CN Ruthenium chloride (RuCl3) (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 16629-19-9 HCAPLUS
CN 2-Thiophenesulfonyl chloride (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 18704-37-5 HCAPLUS
CN 8-Quinolinesulfonyl chloride (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 66715-65-9 HCAPLUS
CN 2-Pyridinesulfonyl chloride (6CI, 7CI, 9CI) (CA INDEX NAME)



RN 115416-38-1 HCAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-(5-aminopentyl)hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **7766-49-6P 51148-67-5P 52355-50-7P**
**83637-49-4P 134179-40-1P 156125-40-5P**
**259270-26-3P 259270-27-4P 338964-01-5P**
**338964-02-6P 338964-03-7P 338964-04-8P**
**338964-05-9P 338964-06-0P 342792-15-8P**
**342792-16-9P 367478-49-7P 367478-57-7P**
**367478-66-8P 367478-71-5P 367478-76-0P**
**367478-80-6P 367478-84-0P 367478-88-4P**
**367478-96-4P 367479-00-3P 367479-05-8P**
**367479-14-9P 367479-19-4P 367479-24-1P**
**367479-27-4P 367479-31-0P 367479-35-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(methods for proteomic anal. using activity based probes for target proteins)

RN 7766-49-6 HCAPLUS
CN 1-Undecene, 11-iodo- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 51148-67-5 HCAPLUS
CN 10-Undecen-1-ol, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)



RN 52355-50-7 HCAPLUS
CN 10-Undecen-1-ol, methanesulfonate (9CI) (CA INDEX NAME)



RN 83637-49-4 HCAPLUS
CN Decanoic acid, 10-[(methylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 134179-40-1 HCAPLUS
CN 4,7,10,13-Tetraoxa-3-silapentadecan-15-ol, 2,2,3,3-tetramethyl- (9CI) (CA INDEX NAME)



RN 156125-40-5 HCAPLUS
CN Phosphonic acid, 10-undecenyl-, diethyl ester (9CI) (CA INDEX NAME)



RN 259270-26-3 HCAPLUS
CN Phosphonic acid, 10-undecenyl-, monoethyl ester (9CI) (CA INDEX NAME)



RN 259270-27-4 HCAPLUS
CN Decanoic acid, 10-(ethoxyhydroxyphosphinyl)- (9CI) (CA INDEX NAME)



RN 338964-01-5 HCAPLUS
CN 4,7,10,13-Tetraoxa-3-silapentadecane, 15-iodo-2,2,3,3-tetramethyl- (9CI) (CA INDEX NAME)



RN 338964-02-6 HCAPLUS
CN Phosphonic acid, (13,13,14,14-tetramethyl-3,6,9,12-tetraoxa-13-silapentadec-1-yl)-, diethyl ester (9CI) (CA INDEX NAME)



RN 338964-03-7 HCAPLUS
CN Phosphonic acid, [2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 338964-04-8 HCAPLUS
CN Phosphonic acid, [13-[(2,5-dioxo-1-pyrrolidinyl)oxy]-13-oxo-3,6,9,12-tetraoxatridec-1-yl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 338964-05-9 HCAPLUS
CN Phosphonic acid, [13-[(2,5-dioxo-1-pyrrolidinyl)oxy]-13-oxo-3,6,9,12-tetraoxatridec-1-yl]-, monoethyl ester (9CI) (CA INDEX NAME)



RN 338964-06-0 HCAPLUS
CN Phosphonofluoridic acid, [13-[(2,5-dioxo-1-pyrrolidinyl)oxy]-13-oxo-3,6,9,12-tetraoxatridec-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 342792-15-8 HCAPLUS
CN 2-Pyridinesulfonic acid, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 342792-16-9 HCAPLUS
CN Decanoic acid, 10-[(2-pyridinylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 367478-49-7 HCAPLUS
CN 10-Undecen-1-ol, benzenesulfonate (9CI) (CA INDEX NAME)



RN 367478-57-7 HCAPLUS

CN Benzenesulfonic acid, 4-methoxy-, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 367478-66-8 HCAPLUS
CN 1-Butanesulfonic acid, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 367478-71-5 HCAPLUS
CN 1-Octanesulfonic acid, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 367478-76-0 HCAPLUS
CN Benzenesulfonic acid, 4-nitro-, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 367478-80-6 HCAPLUS
CN 8-Quinolinesulfonic acid, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 367478-84-0 HCAPLUS
CN 2-Naphthalenesulfonic acid, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 367478-88-4 HCAPLUS
CN 2-Thiophenesulfonic acid, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 367478-96-4 HCAPLUS
CN Decanoic acid, 10-[(phenylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 367479-00-3 HCAPLUS
CN Decanoic acid, 10-[[(4-methylphenyl)sulfonyl]oxy]- (9CI) (CA INDEX NAME)



RN 367479-05-8 HCAPLUS
CN Decanoic acid, 10-[[(4-methoxyphenyl)sulfonyl]oxy]- (9CI) (CA INDEX NAME)



RN 367479-14-9 HCAPLUS
CN Decanoic acid, 10-[(butylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 367479-19-4 HCAPLUS
CN Decanoic acid, 10-[(octylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 367479-24-1 HCAPLUS
CN Decanoic acid, 10-[[(4-nitrophenyl)sulfonyl]oxy]- (9CI) (CA INDEX NAME)



RN 367479-27-4 HCAPLUS
CN Decanoic acid, 10-[(8-quinolinylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 367479-31-0 HCAPLUS
CN Decanoic acid, 10-[(2-naphthalenylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 367479-35-4 HCAPLUS
CN Decanoic acid, 10-[(2-thienylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



IT **367944-46-5 367944-47-6 367944-49-8**
**367944-51-2 367944-54-5 368436-43-5**
**368436-44-6 368436-45-7 368436-46-8**
**368436-47-9**
RL: PRP (Properties)
(unclaimed sequence; methods for proteomic anal. using activity based probes for target proteins)
RN 367944-46-5 HCAPLUS
CN L-Arginine, glycyl-L-phenylalanyl-L-valyl-L-valyl-L-alanyl-L-alanyl-L-isoleucyl-L-.alpha.-glutamyl-L-histidyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367944-47-6 HCAPLUS
CN L-Arginine, L-glutaminyl-L-alanyl-L-phenylalanyl-L-isoleucylglycyl-L-seryl-L-prolyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 367944-49-8 HCAPLUS
CN L-Lysine, L-valyl-L-phenylalanyl-L-alanyl-L-asparaginyl-L-alanyl-L-tyrosyl-L-leucyl-L-seryl-L-.alpha.-aspartyl-L-leucylglycylglycyl-L-seryl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

PAGE 2-B



RN 367944-51-2 HCAPLUS
CN L-Lysine, L-isoleucyl-L-phenylalanyl-L-isoleucyl-L-asparaginyl-L-asparaginyl-L-.alpha.-glutamyl-L-tryptophyl-L-histidyl-L-.alpha.-aspartyl-L-seryl-L-valyl-L-serylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



RN 367944-54-5 HCAPLUS
CN L-Arginine, L-isoleucyl-L-histidylglycyl-L-glutaminyl-L-threonyl-L-isoleucyl-L-prolyl-L-seryl-L-.alpha.-aspartylglycyl-L-.alpha.-aspartyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-phenylalanyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 368436-43-5 HCAPLUS
CN L-Lysine, L-phenylalanyl-L-.alpha.-glutamyl-L-isoleucyl-L-phenylalanylglycyl-L-prolyl-L-valyl-L-glutaminyl-L-glutaminyl-L-isoleucyl-L-methionyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

Pr-i

PAGE 2-A

RN 368436-44-6 HCAPLUS
CN L-Arginine, L-isoleucyl-L-phenylalanyl-L-valyl-L-.alpha.-glutamyl-L-phenylalanyl-L-seryl-L-valyl-L-tyrosyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-phenylalanyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 368436-45-7 HCAPLUS
CN L-Lysine, L-leucyl-L-.alpha.-glutamyl-L-leucylglycyl-L-.alpha.-glutamyl-L-histidylglycyl-L-leucyl-L-tyrosyl-L-.alpha.-glutamyl-L-tyrosyl-L-threonyl-L-phenylalanyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 368436-46-8 HCAPLUS
CN L-Arginine, glycyl-L-phenylalanyl-L-phenylalanyl-L-valyl-L-glutaminyl-L-prolyl-L-threonyl-L-tyrosyl-L-phenylalanyl-L-seryl-L-asparaginyl-L-valyl-L-threonyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

PAGE 2-A



PAGE 2-B



RN 368436-47-9 HCAPLUS
CN L-Lysine, L-valyl-L-valyl-L-leucylglycyl-L-asparaginyl-L-leucyl-L-prolyl-L-threonyl-L-glutaminylglycyl-L-isoleucyl-L-asparaginyl-L-glutaminylglycyl-L-prolyl-L-glutaminyl-L-isoleucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



L8 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:763309 HCAPLUS
DOCUMENT NUMBER: 135:315597
TITLE: Methods for bioactivity screening of candidate compounds using activity based probes
INVENTOR(S): **Cravatt, Benjamin F.; Sorensen, Erik ; Patricelli, Matthew; Lovato, Martha; Adam, Gregory**
PATENT ASSIGNEE(S): Scripps Research Institute, USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001077668 | A2 | 20011018 | WO 2000-US34167 | 20001215 |
| WO 2001077668 | A3 | 20020606 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2002045194 | A1 | 20020418 | US 2000-738954 | 20001215 |
| US 2002040275 | A1 | 20020404 | US 2001-836148 | 20010416 |
| US 2002064799 | A1 | 20020530 | US 2001-836145 | 20010416 |
| US 2002182652 | A1 | 20021205 | US 2002-158498 | 20020529 |

PRIORITY APPLN. INFO.:
US 2000-195954P P 20000410
US 2000-212891P P 20000620
US 2000-222532P P 20000802
US 2000-738271 A1 20001215
US 2000-738954 A1 20001215

OTHER SOURCE(S): MARPAT 135:315597

AB The present invention provides methods for analyzing proteomes, as cells or lysates. The anal. is based on the use of probes that have specificity to the active form of proteins, particularly enzymes and receptors. The probes can be identified in different ways. In accordance with the present invention, a method is provided for generating and screening compd. libraries that are used for the identification of lead mols., and for the parallel identification of their biol. targets. By appending specific functionalities and/or groups to one or more binding moieties,

the reactive functionalities gain binding affinity and specificity for particular proteins and classes of proteins. Such libraries of candidate compds., referred to herein as activity-based probes, or ABPs, are used to screen for one or more desired biol. activities or target proteins.

IT **38078-09-0**, (Diethylamino)sulfur trifluoride
RL: RCT (Reactant); RACT (Reactant or reagent)
(DAST; methods for bioactivity screening of candidate compds. using activity based probes)
RN 38078-09-0 HCAPLUS
CN Sulfur, (N-ethylethanaminato)trifluoro-, (T-4)- (9CI) (CA INDEX NAME)



IT **259270-28-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(FP-biotin; methods for bioactivity screening of candidate compds. using activity based probes)
RN 259270-28-5 HCAPLUS
CN Phosphonofluoridic acid, [10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **259270-29-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(FP-fluorescein; methods for bioactivity screening of candidate compds. using activity based probes)
RN 259270-29-6 HCAPLUS
CN Phosphonofluoridic acid, [10-[[5-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]pentyl]amino]-10-oxodecyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT **9028-86-8**, Aldehyde dehydrogenase
RL: ANT (Analyte); PRP (Properties); ANST (Analytical study)
(cytosolic class I; methods for bioactivity screening of candidate compds. using activity based probes)
RN 9028-86-8 HCAPLUS
CN Dehydrogenase, aldehyde (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **9027-41-2**, Hydrolase
RL: ANT (Analyte); CAT (Catalyst use); PRP (Properties); ANST (Analytical study); USES (Uses)
(methods for bioactivity screening of candidate compds. using activity based probes)
RN 9027-41-2 HCAPLUS
CN Hydrolase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **342792-17-0P 342792-18-1P 342792-19-2P**
**342792-20-5P 342792-21-6P 342792-22-7P**
**342792-23-8P 342792-24-9P 342792-25-0P**
**342792-26-1P 342792-27-2P 367480-61-3P**
RL: ARG (Analytical reagent use); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)
(methods for bioactivity screening of candidate compds. using activity based probes)
RN 342792-17-0 HCAPLUS
CN 2-Pyridinesulfonic acid, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342792-18-1 HCAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-2-oxo-N-[5-[[1-oxo-10-[(phenylsulfonyl)oxy]decyl]amino]pentyl]-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342792-19-2 HCAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-N-[5-[[10-[[(4-methylphenyl)sulfonyl]oxy]-1-oxodecyl]amino]pentyl]-2-oxo-, (3aS,4S,6aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342792-20-5 HCAPLUS
CN Benzenesulfonic acid, 4-methoxy-, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342792-21-6 HCAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-N-[5-[[10-[(methylsulfonyl)oxy]-1-oxodecyl]amino]pentyl]-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342792-22-7 HCAPLUS
CN 1-Butanesulfonic acid, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342792-23-8 HCAPLUS
CN 1-Octanesulfonic acid, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl

ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342792-24-9 HCAPLUS
CN Benzenesulfonic acid, 4-nitro-, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342792-25-0 HCAPLUS
CN 8-Quinolinesulfonic acid, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 342792-26-1 HCAPLUS
CN 2-Naphthalenesulfonic acid, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 342792-27-2 HCAPLUS
CN 2-Thiophenesulfonic acid, 10-[[5-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]pentyl]amino]-10-oxodecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 367480-61-3 HCAPLUS
CN Phosphonofluoridic acid, [25-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-13,21-dioxo-3,6,9,12-tetraoxa-14,20-diazapentacos-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **16156-52-8P 117800-97-2P 126092-21-5P**
RL: ARU (Analytical role, unclassified); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation)
(methods for bioactivity screening of candidate compds. using activity based probes)
RN 16156-52-8 HCAPLUS
CN Methanesulfonic acid, octyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 117800-97-2 HCAPLUS
CN 2-Pyridinesulfonic acid, octyl ester (9CI) (CA INDEX NAME)



RN 126092-21-5 HCAPLUS
CN 2-Pyridinesulfonic acid, ethyl ester (9CI) (CA INDEX NAME)



IT **52-90-4**, L-Cysteine, properties **56-45-1**, L-Serine, properties **56-84-8**, L-Aspartic acid, properties **56-86-0**, L-Glutamic acid, properties **71-00-1**, L-Histidine, properties **107-29-9D**, .alpha.-halo derivs. **7723-14-0D**, Phosphorus, fluoro derivs., properties **7782-41-4**, Fluorine, properties **13537-32-1D**, Fluorophosphoric acid, derivs.
RL: PRP (Properties)
(methods for bioactivity screening of candidate compds. using activity based probes)
RN 52-90-4 HCAPLUS
CN L-Cysteine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 56-45-1 HCAPLUS
CN L-Serine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 56-84-8 HCAPLUS
CN L-Aspartic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 56-86-0 HCAPLUS
CN L-Glutamic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 71-00-1 HCAPLUS
CN L-Histidine (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 107-29-9 HCAPLUS
CN Acetaldehyde, oxime (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 7723-14-0 HCAPLUS
CN Phosphorus (8CI, 9CI) (CA INDEX NAME)

RN 7782-41-4 HCAPLUS
CN Fluorine (8CI, 9CI) (CA INDEX NAME)

RN 13537-32-1 HCAPLUS
CN Phosphorofluoridic acid (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



IT **58-85-5**, Biotin
RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)
(methods for bioactivity screening of candidate compds. using activity based probes)
RN 58-85-5 HCAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **93-11-8**, 2-Naphthalenesulfonyl chloride **98-09-9**, Benzenesulfonyl chloride **98-59-9 98-68-0 98-74-8 111-87-5**, 1-Octanol, reactions **112-43-6**, 10-Undecen-1-ol **112-60-7 121-44-8**, Triethylamine, reactions **122-52-1**, Triethylphosphite **124-63-0**, Methanesulfonyl chloride **2386-60-9**, 1-Butanesulfonyl chloride **2857-97-8**, Trimethylsilyl bromide **6066-82-6**, N-Hydroxysuccinimide **7681-82-5**, Sodium iodide (NaI), reactions **7795-95-1**, 1-Octanesulfonyl chloride **10049-08-8**, Ruthenium chloride (RuCl3) **16629-19-9**, 2-Thiophenesulfonyl chloride **18704-37-5**, 8-Quinolinesulfonyl chloride **66715-65-9**, 2-Pyridylsulfonyl chloride **115416-38-1**, 5-(Biotinamido)pentylamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(methods for bioactivity screening of candidate compds. using activity based probes)
RN 93-11-8 HCAPLUS
CN 2-Naphthalenesulfonyl chloride (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 98-09-9 HCAPLUS
CN Benzenesulfonyl chloride (8CI, 9CI) (CA INDEX NAME)



RN 98-59-9 HCAPLUS
CN Benzenesulfonyl chloride, 4-methyl- (9CI) (CA INDEX NAME)



RN 98-68-0 HCAPLUS
CN Benzenesulfonyl chloride, 4-methoxy- (9CI) (CA INDEX NAME)



RN 98-74-8 HCAPLUS
CN Benzenesulfonyl chloride, 4-nitro- (9CI) (CA INDEX NAME)



RN 111-87-5 HCAPLUS
CN 1-Octanol (9CI) (CA INDEX NAME)



RN 112-43-6 HCAPLUS
CN 10-Undecen-1-ol (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 112-60-7 HCAPLUS
CN Ethanol, 2,2'-[oxybis(2,1-ethanediyloxy)]bis- (9CI) (CA INDEX NAME)



RN 121-44-8 HCAPLUS
CN Ethanamine, N,N-diethyl- (9CI) (CA INDEX NAME)



RN 122-52-1 HCAPLUS
CN Phosphorous acid, triethyl ester (8CI, 9CI) (CA INDEX NAME)



RN 124-63-0 HCAPLUS
CN Methanesulfonyl chloride (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 2386-60-9 HCAPLUS
CN 1-Butanesulfonyl chloride (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 2857-97-8 HCAPLUS
CN Silane, bromotrimethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 6066-82-6 HCAPLUS
CN 2,5-Pyrrolidinedione, 1-hydroxy- (9CI) (CA INDEX NAME)



RN 7681-82-5 HCAPLUS
CN Sodium iodide (NaI) (9CI) (CA INDEX NAME)



RN 7795-95-1 HCAPLUS
CN 1-Octanesulfonyl chloride (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 10049-08-8 HCAPLUS
CN Ruthenium chloride (RuCl3) (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 16629-19-9 HCAPLUS
CN 2-Thiophenesulfonyl chloride (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 18704-37-5 HCAPLUS
CN 8-Quinolinesulfonyl chloride (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 66715-65-9 HCAPLUS
CN 2-Pyridinesulfonyl chloride (6CI, 7CI, 9CI) (CA INDEX NAME)



RN 115416-38-1 HCAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-(5-aminopentyl)hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **7766-49-6P 51148-67-5P 52355-50-7P**
**83637-49-4P 134179-40-1P 156125-40-5P**
**259270-26-3P 259270-27-4P 338964-01-5P**
**338964-02-6P 338964-03-7P 338964-04-8P**
**338964-05-9P 338964-06-0P 342792-15-8P**
**342792-16-9P 367478-49-7P 367478-57-7P**
**367478-66-8P 367478-71-5P 367478-76-0P**
**367478-80-6P 367478-84-0P 367478-88-4P**
**367478-96-4P 367479-00-3P 367479-05-8P**
**367479-14-9P 367479-19-4P 367479-24-1P**
**367479-27-4P 367479-31-0P 367479-35-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(methods for bioactivity screening of candidate compds. using activity based probes)
RN 7766-49-6 HCAPLUS
CN 1-Undecene, 11-iodo- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 51148-67-5 HCAPLUS
CN 10-Undecen-1-ol, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)



RN 52355-50-7 HCAPLUS
CN 10-Undecen-1-ol, methanesulfonate (9CI) (CA INDEX NAME)



RN 83637-49-4 HCAPLUS
CN Decanoic acid, 10-[(methylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 134179-40-1 HCAPLUS
CN 4,7,10,13-Tetraoxa-3-silapentadecan-15-ol, 2,2,3,3-tetramethyl- (9CI) (CA INDEX NAME)



RN 156125-40-5 HCAPLUS
CN Phosphonic acid, 10-undecenyl-, diethyl ester (9CI) (CA INDEX NAME)



RN 259270-26-3 HCAPLUS
CN Phosphonic acid, 10-undecenyl-, monoethyl ester (9CI) (CA INDEX NAME)



RN 259270-27-4 HCAPLUS
CN Decanoic acid, 10-(ethoxyhydroxyphosphinyl)- (9CI) (CA INDEX NAME)



RN 338964-01-5 HCAPLUS
CN 4,7,10,13-Tetraoxa-3-silapentadecane, 15-iodo-2,2,3,3-tetramethyl- (9CI) (CA INDEX NAME)



RN 338964-02-6 HCAPLUS
CN Phosphonic acid, (13,13,14,14-tetramethyl-3,6,9,12-tetraoxa-13-silapentadec-1-yl)-, diethyl ester (9CI) (CA INDEX NAME)



RN 338964-03-7 HCAPLUS
CN Phosphonic acid, [2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 338964-04-8 HCAPLUS
CN Phosphonic acid, [13-[(2,5-dioxo-1-pyrrolidinyl)oxy]-13-oxo-3,6,9,12-tetraoxatridec-1-yl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 338964-05-9 HCAPLUS
CN Phosphonic acid, [13-[(2,5-dioxo-1-pyrrolidinyl)oxy]-13-oxo-3,6,9,12-tetraoxatridec-1-yl]-, monoethyl ester (9CI) (CA INDEX NAME)



RN 338964-06-0 HCAPLUS
CN Phosphonofluoridic acid, [13-[(2,5-dioxo-1-pyrrolidinyl)oxy]-13-oxo-3,6,9,12-tetraoxatridec-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 342792-15-8 HCAPLUS
CN 2-Pyridinesulfonic acid, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 342792-16-9 HCAPLUS
CN Decanoic acid, 10-[(2-pyridinylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 367478-49-7 HCAPLUS
CN 10-Undecen-1-ol, benzenesulfonate (9CI) (CA INDEX NAME)



RN 367478-57-7 HCAPLUS
CN Benzenesulfonic acid, 4-methoxy-, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 367478-66-8 HCAPLUS
CN 1-Butanesulfonic acid, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 367478-71-5 HCAPLUS
CN 1-Octanesulfonic acid, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 367478-76-0 HCAPLUS
CN Benzenesulfonic acid, 4-nitro-, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 367478-80-6 HCAPLUS
CN 8-Quinolinesulfonic acid, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 367478-84-0 HCAPLUS
CN 2-Naphthalenesulfonic acid, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 367478-88-4 HCAPLUS
CN 2-Thiophenesulfonic acid, 10-undecenyl ester (9CI) (CA INDEX NAME)



RN 367478-96-4 HCAPLUS
CN Decanoic acid, 10-[(phenylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 367479-00-3 HCAPLUS
CN Decanoic acid, 10-[[(4-methylphenyl)sulfonyl]oxy]- (9CI) (CA INDEX NAME)



RN 367479-05-8 HCAPLUS
CN Decanoic acid, 10-[[(4-methoxyphenyl)sulfonyl]oxy]- (9CI) (CA INDEX NAME)



RN 367479-14-9 HCAPLUS
CN Decanoic acid, 10-[(butylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 367479-19-4 HCAPLUS
CN Decanoic acid, 10-[(octylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 367479-24-1 HCAPLUS
CN Decanoic acid, 10-[[(4-nitrophenyl)sulfonyl]oxy]- (9CI) (CA INDEX NAME)



RN 367479-27-4 HCAPLUS
CN Decanoic acid, 10-[(8-quinolinylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 367479-31-0 HCAPLUS
CN Decanoic acid, 10-[(2-naphthalenylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 367479-35-4 HCAPLUS
CN Decanoic acid, 10-[(2-thienylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



IT **367944-46-5 367944-47-6 367944-48-7**
**367944-49-8 367944-50-1 367944-51-2**
**367944-53-4 367944-54-5 367944-55-6**
**367944-57-8**
RL: PRP (Properties)
(unclaimed sequence; methods for bioactivity screening of candidate compds. using activity based probes)
RN 367944-46-5 HCAPLUS
CN L-Arginine, glycyl-L-phenylalanyl-L-valyl-L-valyl-L-alanyl-L-alanyl-L-isoleucyl-L-.alpha.-glutamyl-L-histidyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367944-47-6 HCAPLUS
CN L-Arginine, L-glutaminyl-L-alanyl-L-phenylalanyl-L-isoleucylglycyl-L-seryl-L-prolyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 367944-48-7 HCAPLUS
CN L-Lysine, L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-phenylalanylglycyl-L-prolyl-L-valyl-L-glutaminyl-L-glutaminyl-L-isoleucyl-L-methionyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

Pr-i

PAGE 2-A

RN 367944-49-8 HCAPLUS
CN L-Lysine, L-valyl-L-phenylalanyl-L-alanyl-L-asparaginyl-L-alanyl-L-tyrosyl-L-leucyl-L-seryl-L-.alpha.-aspartyl-L-leucylglycylglycyl-L-seryl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



RN 367944-50-1 HCAPLUS
CN L-Arginine, L-isoleucyl-L-phenylalanyl-L-tyrosyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-seryl-L-valyl-L-tyrosyl-L-.alpha.-aspartyl-L-.alpha.-

glutamyl-L-.alpha.-glutamyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 367944-51-2 HCAPLUS
CN L-Lysine, L-isoleucyl-L-phenylalanyl-L-isoleucyl-L-asparaginyl-L-asparaginyl-L-.alpha.-glutamyl-L-tryptophyl-L-histidyl-L-.alpha.-aspartyl-L-seryl-L-valyl-L-serylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



RN 367944-53-4 HCAPLUS
CN L-Lysine, L-.alpha.-glutamyl-L-leucylglycyl-L-.alpha.-glutamyl-L-histidylglycyl-L-leucyl-L-tyrosyl-L-.alpha.-glutamyl-L-tyrosyl-L-threonyl-L-.alpha.-glutamyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 367944-54-5 HCAPLUS
CN L-Arginine, L-isoleucyl-L-histidylglycyl-L-glutaminyl-L-threonyl-L-isoleucyl-L-prolyl-L-seryl-L-.alpha.-aspartylglycyl-L-.alpha.-aspartyl-L-

isoleucyl-L-phenylalanyl-L-threonyl-L-phenylalanyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 367944-55-6 HCAPLUS
CN L-Arginine, glycyl-L-phenylalanyl-L-phenylalanyl-L-valyl-L-glutaminyl-L-prolyl-L-threonyl-L-valyl-L-phenylalanyl-L-seryl-L-asparaginyl-L-valyl-L-threonyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 367944-57-8 HCAPLUS
CN L-Lysine, L-tyrosyl-L-valyl-L-leucylglycyl-L-asparaginyl-L-prolyl-L-leucyl-L-threonyl-L-glutaminylglycyl-L-isoleucyl-L-asparaginyl-L-glutaminylglycyl-L-prolyl-L-glutaminyl-L-isoleucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



```
=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    13.58      36.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -1.30      -2.60

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:37:17 ON 26 AUG 2003
```